Satellos Bioscience Inc (MSCLF)

[Jumpinjackas]

What is the market potential for iCo-007?

What about iCo-008?
Given the explosive increase in diabetic population and the “aging” demographic, the market for iC-007 is significant. By way of comparison, Eylea, a product that was recently introduced to the wet age-related macular degeneration market (Wet AMD), a “sister” disease to DME, posted revenue of about $838 million in 2012, the first year of introduction, and $314 million for Q1 2013. And that was based simply on being able to reduce the frequency of patient injections from once a month – the typical treatment regime using the current standard of care, a drug called Lucentis – to once every two months using Eylea. We believe iCo-007 can reduce the injection frequency even further, and has other advantages in product differentiation as well.


For iCo-008, the VKC/AKC markets are much smaller, but the advantage is being able to price a product at a premium given the lack of competition and hence create a highly profitable drug. Gilead was very successful with this business strategy. Further, iCo-008 has additional applications in other systemic inflammatory related diseases, such as ulcerative colitis and asthma so there is a meaningful opportunity to generate revenue across a number of disease indications.